Financial Performance & Growth - Sparebanken Norge's Q2 2025 presentation highlights strong financial performance and growth following a legal merger on May 2, 2025 [2, 4] - The group's cost-to-income ratio for Q2 2025 is 29%, positioning it favorably compared to peers [8, 9] - The company reported a pro forma Return on Equity (ROE) of 18% for Q2 2025 [16] - Net interest income increased, reaching NOK 2711 million in Q2 2025 [42, 43] - Underlying cost growth is approximately 2.3%, with a pro forma cost-to-income ratio of 29% (27.4% adjusted for merger costs) [49] Lending & Deposits - The company has a gross loans portfolio of NOK 463 billion [11, 12] - Retail customer lending grew by 3.7% year-to-date, while corporate customer lending grew by 5.1% year-to-date [6] - Retail customer deposits show year-on-year growth of 11.2% [36] - Mortgage loan delinquencies (90 days) remain below 0.1% [59] Subsidiaries & Associated Companies - Eiendomsmegler Norge achieved a year-to-date pre-tax profit of NOK 49 million [75] - Borea Asset Management has Assets under Management (AUM) of NOK 18.7 billion [77] - Frende Holding's annualized ROE was 23.6% in the first half of 2025 [83] Capital Adequacy & Synergies - The Common Equity Tier 1 (CET1) ratio is 18.4% [17, 69, 70] - Realized capital synergies of approximately NOK 2 billion in Q2 2025 due to the implementation of CRR3/Basel IV [123] - Cost synergies are estimated to be greater than NOK 425 million [111, 112, 119] Future Targets & Strategy - The company aims for a Return on Equity (ROE) greater than 13% and a CET1 capital ratio greater than 16% by 2026-2028 [112, 129] - Bulder is targeting NOK 83 billion in lending [111] - Borea Asset Management is targeting > NOK 34 billion in AUM by the end of 2028 [195]

Second Quarter 2025 Overall Results - Sea Limited reported strong and healthy growth across all its businesses in the second quarter of 2025[8] - GAAP Revenue reached $53 billion[12], while Gross Profit was $24 billion[12], and Operating Income was $4877 million[12] - The company's Adjusted EBITDA was $8292 million[14] E-commerce (Shopee) - E-commerce GAAP Revenue increased to $38 billion[9] - Shopee's GMV grew 25% YoY in the first half of 2025, with expectations for continued growth in the third quarter[23] - Content-driven orders accounted for over 20% of physical goods order volume in 2Q 2025[22] Digital Financial Services - Loans Principal Outstanding grew over 90% YoY in 2Q 2025, reaching $69 billion[38] - The company added over 4 million first-time borrowers in 2Q 2025, bringing consumer and SME loans active users to over 30 million[38] - Digital Financial Services GAAP Revenue was $8828 million, with Adjusted EBITDA at $2553 million[17] Digital Entertainment (Garena) - Digital Entertainment Bookings were $6613 million[9], with a YoY increase of 23%[51] - Free Fire sustained a massive global user base of over 100 million average DAU[51] - The company is raising its full-year guidance for Garena, expecting bookings to grow more than 30% YoY in 2025[50]

Company Overview and Strategy - Lifecore is a fully integrated CDMO specializing in sterile injectable pharmaceuticals[9], aiming for a revenue CAGR of 12%+ and Adjusted EBITDA margins of 25%+ in the mid-term[7, 89] - The company projects revenues of $74 million - $76 million and Adjusted EBITDA of $12 million - $14 million for the 7-month transition period (May 26 – Dec 31, 2025)[10] - Lifecore has expanded capacity and revenue potential of approximately $300 million annually[7, 89] Market and Growth Drivers - The global injectable CDMO market is a $10 billion market with a +10% CAGR[24] - The global CDMO market is a $120 billion market with a +8% CAGR[24] - The Hyaluronic Acid market is a $9.8 billion market with a +7% CAGR[24] Financial Performance and Outlook - Fiscal Year 2025 revenues reached $128.9 million, a +0.5% increase compared to FY24[82] - Fiscal Year 2025 Adjusted EBITDA was $19.5 million, a -$0.7 million decrease compared to FY24[82] - The company is targeting a mid-term Adjusted EBITDA margin of 25%+[75] Pipeline and New Business - The total pipeline represents $150 million - $200 million in incremental commercial revenue potential[41] - The company has a strong and diverse pipeline with 11 active late-stage projects and 19 early-mid stage projects[42] - The company is expanding its target markets beyond high-viscosity legacy, including mAbs, complex generics, biologics, and GLP-1[55]

Financial Performance - Revenue increased by 9.3% to £297.8 million in H1 2025, compared to £272.4 million in H1 2024[13] - EBIT increased by 2.3% to £44.6 million in H1 2025[12] - The EBIT margin decreased by 100 bps to 15.0% due to increased NI and NMW costs[12,13] - Dividend per share increased by 2.4% to 4.2p[12,13] - Operating cash conversion was 65.1%, expected to be around 90% for the full year[12,39] Business Segment Performance - Climate Management Solutions (CMS) revenue increased by 11.5% to £87.6 million[27] - Water Management Solutions (WMS) revenue increased by 10.4% to £86.2 million, but underlying operating profit decreased by 43.6% to £4.0 million[31] - Sustainable Building Solutions (SBS) revenue increased by 7.9% to £120.2 million, and underlying operating profit increased by 19.6% to £28.1 million[35] Strategic Initiatives and Outlook - The company maintains full-year expectations, focusing on new solutions and market share gains[9] - Structural tailwinds from UK regulatory changes and expected housebuilding increases are expected to drive medium-term growth[9] - The company is leveraging the Genuit Business System (GBS) to improve productivity and cash flows[61,67]

Financial Performance - Service revenues reached ₱97.1 billion, a slight increase from ₱96.9 billion in 1H24[4] - Cash Opex decreased by 3% from ₱43.0 billion to ₱41.6 billion[4] - EBITDA grew by 3% to ₱55.5 billion with a 52% margin, compared to ₱53.9 billion in 1H24[4] - Depreciation & Amortization increased by 7% to ₱26.2 billion[4] - Net Financing Costs increased significantly by 27% to ₱8.4 billion[4] - Telco Core Income decreased by 4% to ₱17.2 billion[4] - Core Income increased slightly by 1% to ₱17.6 billion[4] Segment Performance - Home broadband revenues totaled ₱30.4 billion, a 4% increase[8] - Fiber revenues within the home segment grew by 7% to ₱29.5 billion[8] - Enterprise revenues totaled ₱23.5 billion, impacted by headwinds[8, 14] - Individual revenues totaled ₱42.3 billion[8] - Mobile data revenues accounted for 89% of individual revenues, totaling ₱37.4 billion[8] Key Growth Areas - Home fiber net adds reached 169,000, a 3X increase compared to 1H24[11, 12] - Over 80% of new home accounts opted for higher-value plans[11] - Total active data users reached 41.6 million[22] - Total mobile data traffic increased by 5% to 2,766 petabytes[22] - Data Center Colocation revenue increased by 36%[17] - Cyber Security Services revenue increased by 24%[17]

Q2 2025 results Conference call NTG Nordic Transport Group August 12, 2025, 10:00 AM CEST Forward looking statements This presentation has been prepared for information purposes only. This presentation (i) is by necessity a summary of more detailed information, (ii) is not intended and should not be used to form the basis of any investment decision, and (iii) does not purport to be full or complete. The Company has not independently verified the information contained herein and does not undertake any obliga ...

Financial Performance - SGH's revenue increased by 1% to $10744 million[12] - EBIT increased by 8% to $1537 million[12] - NPAT increased by 9% to $924 million[12] - Operating cash flow increased significantly by 49% to $1951 million[12] - The company's final dividend increased by 17% to 62cps[22] Business Unit Performance - WesTrac's revenue increased by 4% to $6100 million[39] - Boral's revenue increased by 1% to $3603 million, with EBIT up by 26% to $468 million[57] - Coates' revenue decreased by 9% to $1041 million[76] - Beach Energy's revenue increased by 13% to $1997 million, with production up by 9% to 197 million barrels of oil equivalent (mmboe)[93] Safety and Sustainability - Lost Time Injury Frequency Rate (LTIFR) and Total Recordable Injury Frequency Rate (TRIFR) improved by 38% and 31% respectively[35] Capital Management - Adjusted Net Debt to EBITDA (Leverage) decreased by 10% year-over-year, falling below 2x[22]

Financial Performance - Yalla Group achieved revenues of US$846 million in 2Q2025, compared to US$812 million in 2Q2024[34, 55] - Net income for 2Q2025 was US$365 million, representing a net margin of 432%[12, 34] - Average Monthly Active Users (MAUs) increased to 42421 thousand in 2Q2025, an 88% year-over-year growth[36] - The company maintains a strong cash flow position, with cash and cash equivalents, restricted cash, term deposits, and short-term investments totaling US$7041 million as of June 2025[53] Operational Efficiency - Cost of revenues decreased to US$279 million in 2Q2025, representing 330% of total revenues[38] - Selling and marketing expenses remained stable at US$87 million, accounting for 102% of total revenues[40] - General and administrative expenses increased to US$90 million, representing 106% of total revenues[43] - Technology and product development expenses increased to US$83 million, accounting for 99% of total revenues[46] Strategic Initiatives - The company repurchased 6230299 ADSs for approximately US$41 million in 1H2025 and is committed to repurchasing US$50 million for the full year[27] - All shares repurchased in 2025, totaling 6230299 ADSs, have been canceled[28]

For personal use only Gentrack Group CCG Boston 2025 12 Aug 2025 [NZX/ASX: GTK] © Gentrack 2025. All rights reserved. This document is the intellectual property of Gentrack. LEGAL NOTICE This presentation is provided by Gentrack Group Limited (NZCN 3768390) (Gentrack) to provide summary information about Gentrack and its subsidiaries (the Group). Statements in this presentation are made only as at 12 August 2025 and the information in this presentation remains subject to change without notice. The informati ...

Financial Highlights - FibroGen China sale预计总对价约为2.1亿美元，比最初的指导增加了5000万美元[3] - 通过出售FibroGen China，公司预计可以获得约1.25亿美元的净现金，并将现金流延长至2028年[3] - 公司将偿还Morgan Stanley Tactical Value定期贷款[3] FG-3246 & FG-3180 Program - FG-3246在既往接受大量治疗的转移性去势抵抗性前列腺癌(mCRPC)患者的1期单药治疗研究中，显示出有意义的临床活性，中位rPFS为8.7个月[14, 17] - 在FG-3246联合恩杂鲁胺治疗mCRPC的1b期研究中，观察到有临床意义的疗效信号，初步估计的中位rPFS为10.2个月，71%的可评估患者PSA下降[19] - FG-3246的2期单药治疗试验预计将于2025年第三季度启动，中期结果预计在2026年下半年公布[3, 38] Roxadustat - 在MATTERHORN 3期试验的事后亚组分析中，对于高输血负担的患者，Roxadustat与安慰剂相比显示出输血独立(TI)的益处，在28周内，Roxadustat组有36%的患者达到8周RBC-TI，而安慰剂组只有7%[49, 50] - 计划的关键性3期试验的最终方案预计将于2025年第四季度提交[3, 52]